CompletedNot Applicable

NovoTTF Treatment Signatures in Glioblastoma Patients at Autopsy

United States20 participantsStarted 2017-06-01

Plain-language summary

This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Newly diagnosed glioblastoma, World Health Organization (WHO) grade IV, patients undergoing TTField therapy. * Recurrent glioblastoma WHO grade IV, patients undergoing TTField therapy. Exclusion Criteria: * TTField compliance \< 75%. * Any contraindication to Optune TTField treatment. * Initial brain tumor diagnosis \< WHO grade IV. * Duration of TTField therapy \< 3 months.

What they're measuring

Number of mitotically active cells

Timeframe: At baseline

Number of mitotically inactive cells

Timeframe: At baseline

Mitotic Ratio

Timeframe: At baseline

Trial details

NCT IDNCT03194971

SponsorMedical College of Wisconsin

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-06-04

View on ClinicalTrials.gov More Glioblastoma trials